SEC Form 4 · accession 0000899243-17-008150
Whitehawk Therapeutics, Inc. · WHWK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Mar 15, 2017
Accepted (ET)
Mar 17, 2017 · 8:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422142
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 15, 2017 | P | 560,000 | $5.00 | A | 5,805,550 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.